RBM15 is a novel prognostic biomarker and correlates with immune cell infiltration in lung adenocarcinoma

Abstract Background and Aims: This study aimed to evaluate RBM15 gene expression and the potential effects as a biomarker in LUAD progression. Materials and Methods: The RNA sequencing (RNA-seq) data and clinical data of patients with LUAD were acquired from The Cancer Genome Atlas (TCGA) databases. Kaplan-Meier (K-M) curves were generated to investigate the relationship between RBM15 and the prognosis of patients with LUAD. Gene Ontology (GO) and Reactome enrichment analyses were performed using the “cluster Profiler” R package. Finally, the Tumor Immune Estimation Resource (TIMER)database and CIBERSORT algorithm were used to assess the correlations between RBM15 expression and immune infiltration in LUAD. Results: RBM15 was upregulated in tumor tissue, and it was regarded as an independent prognostic factor in LUAD. The genes co-expressed with RBM15 were closely related to cell cycle checkpoints and M phase signaling pathways. Furthermore, there was a significant correlation between RBM15 gene expression and immune infiltration in LUAD. Conclusion: Our data suggested that RBM15 is critical in LUAD progression, is associated with tumor immune infiltration and served as a valuable potential diagnostic biomarker in patients.